355 related articles for article (PubMed ID: 23678073)
41. Cytomegalovirus Infection Monitoring Based on Interferon Gamma Release Assay in Kidney Transplantation.
De Gracia-Guindo MDC; Ruiz-Fuentes MDC; Galindo-Sacristán P; Osorio-Moratalla JM; Ruiz-Fuentes N; Rodriguez Granger J; Osuna-Ortega A
Transplant Proc; 2018 Mar; 50(2):578-580. PubMed ID: 29579857
[TBL] [Abstract][Full Text] [Related]
42. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
43. Comparison of intracellular cytokine staining versus an ELISA-based assay to assess CMV-specific cell-mediated immunity in high-risk kidney transplant recipients.
Fernández-Ruiz M; Redondo N; Parra P; Ruiz-Merlo T; Rodríguez-Goncer I; Polanco N; González E; López-Medrano F; San Juan R; Navarro D; Andrés A; Aguado JM
J Med Virol; 2023 Apr; 95(4):e28733. PubMed ID: 37185851
[TBL] [Abstract][Full Text] [Related]
44. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
[TBL] [Abstract][Full Text] [Related]
45. CMV specific T cell immunity predicts early viremia after liver transplantation.
Shin KH; Lee HJ; Chang CL; Kim EJ; Lim S; Lee SJ; Ryu JH; Yang K; Choi BH; Lee TB; Lee SM
Transpl Immunol; 2018 Dec; 51():62-65. PubMed ID: 30243982
[TBL] [Abstract][Full Text] [Related]
46. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
[TBL] [Abstract][Full Text] [Related]
47. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation.
Lochmanova A; Lochman I; Tomaskova H; Marsalkova P; Raszka J; Mrazek J; Dedochova J; Martinek A; Brozmanova H; Grundmann M
Transplant Proc; 2010 Nov; 42(9):3574-7. PubMed ID: 21094818
[TBL] [Abstract][Full Text] [Related]
48. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR.
Krawczyk A; Ackermann J; Goitowski B; Trenschel R; Ditschkowski M; Timm J; Ottinger H; Beelen DW; Grüner N; Fiedler M
J Clin Virol; 2018; 99-100():61-66. PubMed ID: 29331844
[TBL] [Abstract][Full Text] [Related]
49. Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients.
Dornieden T; Wilde B; Korth J; Werner K; Horn PA; Witzke O; Lindemann M
J Immunol Res; 2019; 2019():3926175. PubMed ID: 30931336
[TBL] [Abstract][Full Text] [Related]
50. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study.
Manuel O; Husain S; Kumar D; Zayas C; Mawhorter S; Levi ME; Kalpoe J; Lisboa L; Ely L; Kaul DR; Schwartz BS; Morris MI; Ison MG; Yen-Lieberman B; Sebastian A; Assi M; Humar A
Clin Infect Dis; 2013 Mar; 56(6):817-24. PubMed ID: 23196955
[TBL] [Abstract][Full Text] [Related]
51. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients.
Barron MA; Gao D; Springer KL; Patterson JA; Brunvand MW; McSweeney PA; Zeng C; Barón AE; Weinberg A
Clin Infect Dis; 2009 Dec; 49(12):1777-83. PubMed ID: 19911937
[TBL] [Abstract][Full Text] [Related]
52. Quantiferon-Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients.
Paouri B; Soldatou A; Petrakou E; Theodosaki M; Tsentidis C; Kaisari K; Oikonomopoulou C; Matsas M; Goussetis E
Pediatr Transplant; 2018 Aug; 22(5):e13220. PubMed ID: 29777573
[TBL] [Abstract][Full Text] [Related]
53. Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin.
Fernández-Ruiz M; Rodríguez-Goncer I; Parra P; Ruiz-Merlo T; Corbella L; López-Medrano F; Polanco N; González E; San Juan R; Folgueira MD; Andrés A; Aguado JM
Am J Transplant; 2020 Aug; 20(8):2070-2080. PubMed ID: 31991045
[TBL] [Abstract][Full Text] [Related]
54. Early cytomegalovirus-specific T-cell response and estimated glomerular filtration rate identify patients at high risk of infection after renal transplantation.
Leone F; Gigliotti P; Mauro MV; Lofaro D; Greco F; Tenuta R; Perugini D; Papalia T; Mollica A; Perri A; Vizza D; La Russa A; Toteda G; Lupinacci S; Giraldi C; Bonofiglio R
Transpl Infect Dis; 2016 Apr; 18(2):191-201. PubMed ID: 26878346
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of CMV-specific cellular immune response by EliSPOT assay in kidney transplant patients.
Costa C; Balloco C; Sidoti F; Mantovani S; Rittà M; Piceghello A; Fop F; Messina M; Cavallo R
J Clin Virol; 2014 Dec; 61(4):523-8. PubMed ID: 25453571
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the fully automated LIAISON®XL chemiluminescence analyzer for QuantiFERON®-CMV testing in transplant recipients.
Mafi S; Alain S; Hantz S
J Clin Virol; 2023 Sep; 166():105550. PubMed ID: 37527584
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope.
Ohnishi M; Sakurai T; Heike Y; Yamazaki R; Kanda Y; Takaue Y; Mizoguchi H; Kawakami Y
Br J Haematol; 2005 Nov; 131(4):472-9. PubMed ID: 16281937
[TBL] [Abstract][Full Text] [Related]
58. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
59. QuantiFERON-CMV and monitor predict cytomegalovirus, mortality, and graft-versus-host disease in transplant recipients.
Souan L; Jazar HA; Nashwan S; Sughayer MA
J Med Virol; 2023 Nov; 95(11):e29250. PubMed ID: 38009250
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic Usefulness of Cytomegalovirus (CMV)-Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of-Concept Study.
Kim SH; Lee HJ; Kim SM; Jung JH; Shin S; Kim YH; Sung H; Lee SO; Choi SH; Kim YS; Woo JH; Han DJ
Infect Chemother; 2015 Jun; 47(2):105-10. PubMed ID: 26157588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
